An epirubicin–conjugated nanocarrier with MRI function to overcome lethal multidrug-resistant bladder cancer
- 31 May 2012
- journal article
- Published by Elsevier BV in Biomaterials
- Vol. 33 (15), 3919-3930
- https://doi.org/10.1016/j.biomaterials.2012.02.020
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Nanomedicine for targeted cancer therapy: Towards the overcoming of drug resistanceDrug Resistance Updates, 2011
- Optimization of epirubicin nanoparticles using experimental design for enhanced intravesical drug deliveryInternational Journal of Pharmaceutics, 2009
- Pullulan acetate nanoparticles prepared by solvent diffusion method for epirubicin chemotherapyColloids and Surfaces B: Biointerfaces, 2009
- Nanosized cationic hydrogels for drug delivery: preparation, properties and interactions with cellsAdvanced Drug Delivery Reviews, 2001
- Kinetic analysis of translocation through nuclear pore complexesThe EMBO Journal, 2001
- Ceramide glycosylation potentiates cellular multidrug resistanceThe FASEB Journal, 2001
- Multicellular resistance: a paradigm for clinical resistance?Critical Reviews in Oncology/Hematology, 2000
- Nuclear pore complex ion channels (Review)Molecular Membrane Biology, 1994
- What's New in Cytostatic Drug Resistance and PathologyPathology - Research and Practice, 1991
- Mechanisms of multidrug resistance in human tumor cells. The roles of P-glycoprotein, DNA topoisomerase II, and other factorsCancer Treatment Reviews, 1990